458 related articles for article (PubMed ID: 7871047)
1. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
Lublin H; Gerlach J; Peacock L
Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.
Lublin H; Gerlach J; Mørkeberg F
Psychopharmacology (Berl); 1994 Apr; 114(3):495-504. PubMed ID: 7855208
[TBL] [Abstract][Full Text] [Related]
3. Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.
Lublin H; Gerlach J; Peacock L
Clin Neuropharmacol; 1992 Dec; 15(6):448-58. PubMed ID: 1362136
[TBL] [Abstract][Full Text] [Related]
4. The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment.
Peacock L; Lublin H; Gerlach J
Eur J Pharmacol; 1990 Sep; 186(1):49-59. PubMed ID: 1980891
[TBL] [Abstract][Full Text] [Related]
5. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
Peacock L; Hansen L; Mørkeberg F; Gerlach J
Neuropsychopharmacology; 1999 Jan; 20(1):35-43. PubMed ID: 9885783
[TBL] [Abstract][Full Text] [Related]
6. Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans.
Kistrup K; Gerlach J
Pharmacol Toxicol; 1987 Sep; 61(3):157-61. PubMed ID: 2891133
[TBL] [Abstract][Full Text] [Related]
7. D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity.
Marin C; Parashos SA; Kapitzoglou-Logothetis V; Peppe A; Chase TN
Pharmacol Biochem Behav; 1993 May; 45(1):195-200. PubMed ID: 8516358
[TBL] [Abstract][Full Text] [Related]
8. Dopamine receptor agonist- and antagonist-induced behaviors in primates previously treated with dopamine receptor antagonists: the pathogenetic mechanisms of acute oral dyskinesia.
Lublin H
Clin Neuropharmacol; 1995 Dec; 18(6):533-51. PubMed ID: 8681313
[TBL] [Abstract][Full Text] [Related]
9. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
Peacock L; Gerlach J
Eur J Pharmacol; 1993 Jun; 237(2-3):329-40. PubMed ID: 8103465
[TBL] [Abstract][Full Text] [Related]
10. The effects of haloperidol and raclopride in the paw test are influenced similarly by SCH 39166.
Prinssen EP; Ellenbroek BA; Stamatovic B; Cools AR
Eur J Pharmacol; 1993 Feb; 231(2):275-80. PubMed ID: 8095900
[TBL] [Abstract][Full Text] [Related]
11. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
12. Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function.
Glenthøj B
Psychopharmacology (Berl); 1993; 113(2):157-66. PubMed ID: 7855176
[TBL] [Abstract][Full Text] [Related]
13. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors.
Coffin VL; Latranyi MB; Chipkin RE
J Pharmacol Exp Ther; 1989 Jun; 249(3):769-74. PubMed ID: 2567351
[TBL] [Abstract][Full Text] [Related]
14. Extrapyramidal side effects during chronic combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys.
Peacock L; Jensen G; Nicholson K; Gerlach J
Eur Arch Psychiatry Clin Neurosci; 1999; 249(5):221-6. PubMed ID: 10591986
[TBL] [Abstract][Full Text] [Related]
15. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(4):403-12. PubMed ID: 7604140
[TBL] [Abstract][Full Text] [Related]
16. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications.
Braun AR; Laruelle M; Mouradian MM
J Neural Transm (Vienna); 1997; 104(4-5):341-62. PubMed ID: 9295170
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of the locomotor-sensitizing effects of the D2 dopamine agonist bromocriptine by either the D1 antagonist SCH 23390 or the D2 antagonist raclopride.
Wise RA; Carlezon WA
Synapse; 1994 Jul; 17(3):155-9. PubMed ID: 7974197
[TBL] [Abstract][Full Text] [Related]
18. Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents.
Protais P; Chagraoui A; Arbaoui J; Mocaër E
Eur J Pharmacol; 1994 Dec; 271(1):167-77. PubMed ID: 7698199
[TBL] [Abstract][Full Text] [Related]
19. D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats.
Verma A; Kulkarni SK
Psychopharmacology (Berl); 1992; 109(4):477-83. PubMed ID: 1365866
[TBL] [Abstract][Full Text] [Related]
20. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets.
Löschmann PA; Smith LA; Lange KW; Jaehnig P; Jenner P; Marsden CD
Psychopharmacology (Berl); 1991; 105(3):303-9. PubMed ID: 1686813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
